Slides
Page 1
2026 THIRD-QUARTER RESULTS Presentation for investors, analysts and media Basel, October 28, 2026
Page 2
DISCLAIMER This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Gro up as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan,“ "goal," "believe," "proj ect," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward- looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward -looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this presentation. Accordingly, you should not rely on any forward-looking statements contained in this presentation. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this presentation as of the date it is given and does not undertake any obligation to update any statements as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities. 2
Page 3
AGENDA 1 Performance overview Guillaume Daniellot 2 Financial performance Isabelle Wege 3 Strategy update Guillaume Daniellot 4 2026 outlook Guillaume Daniellot 5 Q&A Guillaume Daniellot & Isabelle Wege 3
Page 4
PERFORMANCE OVERVIEW – Guillaume Daniellot, Group CEO –
Page 5
Q3 GROWTH ACCELERATES TO 9.2% Full-year 2026 outlook confirmed Regional performance EMEA & APAC Double-digit organic growth of 10.5% and 10.3%, respectively New efficient treatment solutions SIRIOS APS + F.A.S.T. New full-arch scanning technology and connected workflows shorten treatment time and improve practice profitability Q3 organic growth in 2026 9.2% Accelerated from 8.5% in Q2. Nine-month organic growth reached 8.3% Outlook 20262 140 to 170 bps1 Core EBIT margin expansion and high single-digit organic revenue growth confirmed Supporting Challenger growth NEW NEODENT factory Third factory opened in Curitiba, adding capacity for Neodent’s global expansion Revenue in Q3 2026 667.1 M CHF 2.1 bn revenue in 9M 2026 1 At constant 2025 exchange rates 2 Barring unforeseen events 5
Page 6
GROUP Q3 26 9.2% Q3 25 8.3% 9m 26 8.3% 9m 25 9.6% 11 %* 26 %* 38 %* 25 %* DOUBLE-DIGIT GROWTH IN EMEA AND APAC Regional organic growth in the third quarter and the first nine months of 2026 EMEA Q3 26 10.5% 9M 26 8.9% NAM Q3 26 7.5% 9M 26 7.9% LATAM Q3 26 6.5% 9M 26 12.1% APAC Q3 26 10.3% 9M 26 6.1% *% of Q3 2026 Group revenue Regional share of Group revenue in % 41 24 10 26 9M 2026 NAM LATAM APAC EMEA 6
Page 7
FINANCIAL PERFORMANCE – Isabelle wEge, Group CFO –
Page 8
Regional % share of organic growth 68 38 29 22 Revenue 9M 2025 -60 FX effect Revenue 9M 2026 LATAM 1’950 1’890 APACNAMEMEA 0 Adjusted Revenue base M&A effect 2’047 +8.3% Organic +4.9% Change in organic growth +7.9% +12.1%+8.9% +6.1% 43 25 14 18 9M 2026 APAC LATAM NAM EMEA STRONG RESULTS WITH CONSIDERABLE FX HEADWINDS Revenue development breakdown in CHF million, rounded 8
Page 9
CHINA REGAINS MOMENTUM WHILE VBP 2.0 IS GETTING STARTED • China regained growth momentum in Q3 after several challenging quarters marked by VBP uncertainty • Rules for the next round of VBP for dental implants have not yet been announced, with tender completion expected before year-end and operational implementation anticipated in Q1 2027 • The Group’s portfolio across price segments and local manufacturing capabilities provide a strong foundation for further market share gains Key developments PremiumChallenger Implant market segments in volumes in China 9
Page 10
STRATEGY UPDATE – Guillaume Daniellot, Group CEO –
Page 11
MASSIVE MARKET OPPORTUNITY ACROSS ALL SEGMENTS Source: Straumann Group estimates CHF 20 bn market opportunity globally - 14% Straumann Group market share Market size CHF 6.1BN Implantology RegenerativeS CHF 1.3BN Market share >35% <13% Perform Transform CHF 4.9BN Digital equipment CHF 1.8BN CADCAM Prosthetics CHF 5.7BN <5% Clear aligner 10%+ <5% <5% 11
Page 12
SUPERIOR CUSTOMER EXPERIENCE THROUGH PRODUCT LEADERSHIP × DIGITALIZATION 12 Innovation drives product excellence Digitalization enhances efficiency & clinician experience Straumann FAST Molar Solution Straumann Iexcel implant system Clearcorrect scalloped trimline aligner Sirios X3 intraoral scanner Straumann access cloud-based platform EDUCATION
Page 13
STRAUMANN AXS DEEPENS CUSTOMER RELATIONSHIPS IOS portfolio – multi branding & multi pricing Mid Entry Premium 3Shape TRIOS 5/6 SIRIOS SIRIOS X3 Open-cloud based Straumann axs platform 65 000+ installed scanners 20 000+ active Straumann AXS users AXS customers’ stickiness drives value Reorder rates for AXS customers are substantially higher than for non-AXS customers • Straumann AXS connects clinicians and labs through daily treatment workflows • Connected workflows make repeat ordering easier, creating more opportunities for implant and prosthetic sales *indicative estimate from analysis of gross-contribution-based customer value for AXS users versus non-users13
Page 14
PRODUCT INNOVATION & DIGITALIZATION ENABLE A MORE DIFFERENTIATED OFFERING & INCREASED RECURING REVENUE moLAR Fixed Full Arch Accurate.Fast. Trusted.Simple. At least one patient appointment saved by scanning on the day of surgery* Place Scan same day Restore Up next: the full-arch workflow→ 14
Page 15
SIRIOS APS: SIMPLER IMMEDIATE FULL-ARCH TREATMENT Accelerating adoption of higher-value cases with F.A.S.T. Full Arch treatment solution New Straumann SIRIOS APS Arch Positioning System • Scan: SIRIOS APS captures precise implant positions during surgery, with no expensive specialist scanner needed • Connect: In AXS, clinicians and dental labs work from the same digital case, from scan to final restoration • Benefit: Practices work more cost efficiently and patients get their denture faster SIRIOS APS replaces conventional impressions with a digital scan for the Straumann AXS workflow 15
Page 16
CLEARCORRECT GROWS DOUBLE-DIGIT IN F0CUS MARKETS NEW TOOLS FROM CASE SELECTION TO PATIENT FOLLOW-UP Revenue Growth Double-digit Case Assessment Outcome Simulator RemoteCare A stronger GP offering and a leaner cost base • New tools make aligner treatment easier for general practitioners to offer • Resources focus on markets with the strongest growth potential • Lower production and operating costs 16
Page 17
EDUCATION DRIVES MARKET PENETRATION OF INNOVATIONS 17 September & October events engaged dental professional across key markets Major educational platforms Engaging dental professionals Neodent Symposium in Austin International Esthetics Day 2026 in Copenhagen
Page 18
2026 OUTLOOK – Guillaume Daniellot, Group CEO –
Page 19
OUTLOOK 2026 1 – CONFIRMED 1 as communicated in June 2026, barring unforeseen events • High-single digit organic revenue growth • 140 to 170 basis points improvement of the core EBIT margin at constant 2025 exchange rates Significant growth opportunities in a CHF 20bn+ addressable market with strong fundamentals Proven business model with strong market positions amid continued volatility Strong innovation pipeline and transformation initiatives fueling future growth 19
Page 20
ANY QUESTIONS?
Page 21
CALENDAR OF UPCOMING EVENTS Date Event Location October 29 , 2026 Roadshow Bank of America Paris November 4, 2026 Roadshow J.P. Morgan London November 5, 2026 ZKB Swiss Equity Conference Zurich November 10-11, 2026 UBS European Conference London November 24, 2026 Kepler Cheuvreux Geneva Day Geneva December 7-8, 2026 Roadshow Kepler Cheuvreux Brussels, Amsterdam December 8-9, 2026 Roadshow Barclays New York, Boston December 14-15, 2026 Roadshow ODDO BHF Paris Dec 31 2026 - Feb 23 2027 Quiet period February 24, 2027 Full-year 2026 results Basel 21
Page 22
THANK YOU.